Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 10

1.

KRAS G12V Mutation in Acquired Resistance to Combined BRAF and MEK Inhibition in Papillary Thyroid Cancer.

Owen DH, Konda B, Sipos J, Liu T, Webb A, Ringel MD, Timmers CD, Shah MH.

J Natl Compr Canc Netw. 2019 May 1;17(5):409-413. doi: 10.6004/jnccn.2019.7292.

PMID:
31085763
2.

Degree of MDM2 Amplification Affects Clinical Outcomes in Dedifferentiated Liposarcoma.

Bill KLJ, Seligson ND, Hays JL, Awasthi A, Demoret B, Stets CW, Duggan MC, Bupathi M, Brock GN, Millis SZ, Shakya R, Timmers CD, Wakely PE Jr, Pollock RE, Chen JL.

Oncologist. 2019 Apr 24. pii: theoncologist.2019-0047. doi: 10.1634/theoncologist.2019-0047. [Epub ahead of print]

PMID:
31019022
3.

Genomic risk prediction of aromatase inhibitor-related arthralgia in patients with breast cancer using a novel machine-learning algorithm.

Reinbolt RE, Sonis S, Timmers CD, Fernández-Martínez JL, Cernea A, de Andrés-Galiana EJ, Hashemi S, Miller K, Pilarski R, Lustberg MB.

Cancer Med. 2018 Jan;7(1):240-253. doi: 10.1002/cam4.1256. Epub 2017 Nov 23.

4.

Trametinib for the treatment of IGHV4-34, MAP2K1-mutant variant hairy cell leukemia.

Andritsos LA, Grieselhuber NR, Anghelina M, Rogers KA, Roychowdhury S, Reeser JW, Timmers CD, Freud AG, Blachly JS, Lucas DM, Lozanski G, Jones JA, Williams K, Oakes C, Jones D, Grever MR.

Leuk Lymphoma. 2018 Apr;59(4):1008-1011. doi: 10.1080/10428194.2017.1365853. Epub 2017 Sep 18. No abstract available.

PMID:
28918710
5.

A Transcriptional Signature Identifies LKB1 Functional Status as a Novel Determinant of MEK Sensitivity in Lung Adenocarcinoma.

Kaufman JM, Yamada T, Park K, Timmers CD, Amann JM, Carbone DP.

Cancer Res. 2017 Jan 1;77(1):153-163. doi: 10.1158/0008-5472.CAN-16-1639. Epub 2016 Nov 7.

6.

Dual Inhibition of MEK and PI3K/Akt Rescues Cancer Cachexia through both Tumor-Extrinsic and -Intrinsic Activities.

Talbert EE, Yang J, Mace TA, Farren MR, Farris AB, Young GS, Elnaggar O, Che Z, Timmers CD, Rajasekera P, Maskarinec JM, Bloomston M, Bekaii-Saab T, Guttridge DC, Lesinski GB.

Mol Cancer Ther. 2017 Feb;16(2):344-356. doi: 10.1158/1535-7163.MCT-16-0337. Epub 2016 Nov 3.

7.

Randomized Phase 2 Trial of the Oncolytic Virus Pelareorep (Reolysin) in Upfront Treatment of Metastatic Pancreatic Adenocarcinoma.

Noonan AM, Farren MR, Geyer SM, Huang Y, Tahiri S, Ahn D, Mikhail S, Ciombor KK, Pant S, Aparo S, Sexton J, Marshall JL, Mace TA, Wu CS, El-Rayes B, Timmers CD, Zwiebel J, Lesinski GB, Villalona-Calero MA, Bekaii-Saab TS.

Mol Ther. 2016 Jun;24(6):1150-1158. doi: 10.1038/mt.2016.66. Epub 2016 Apr 4.

8.

Enhanced bioavailability of lycopene when consumed as cis-isomers from tangerine compared to red tomato juice, a randomized, cross-over clinical trial.

Cooperstone JL, Ralston RA, Riedl KM, Haufe TC, Schweiggert RM, King SA, Timmers CD, Francis DM, Lesinski GB, Clinton SK, Schwartz SJ.

Mol Nutr Food Res. 2015 Apr;59(4):658-69. doi: 10.1002/mnfr.201400658. Epub 2015 Mar 10.

9.

Comparison of custom capture for targeted next-generation DNA sequencing.

Samorodnitsky E, Datta J, Jewell BM, Hagopian R, Miya J, Wing MR, Damodaran S, Lippus JM, Reeser JW, Bhatt D, Timmers CD, Roychowdhury S.

J Mol Diagn. 2015 Jan;17(1):64-75. doi: 10.1016/j.jmoldx.2014.09.009.

10.

Bone morphogenetic protein 3B silencing in non-small-cell lung cancer.

Dai Z, Popkie AP, Zhu WG, Timmers CD, Raval A, Tannehill-Gregg S, Morrison CD, Auer H, Kratzke RA, Niehans G, Amatschek S, Sommergruber W, Leone GW, Rosol T, Otterson GA, Plass C.

Oncogene. 2004 Apr 29;23(20):3521-9.

PMID:
15116090

Supplemental Content

Loading ...
Support Center